The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Open accessAbstract
BACKGROUND: In patients with severe hemophilia B, gene therapy that is mediated by a novel self-complementary adeno-associated virus serotype 8 (AAV8) vector has been shown to raise factor IX levels for periods of up to 16 months. We wanted to determine the durability of transgene expression, the vector dose-response relationship, and the level of persistent or late toxicity. METHODS: We evaluated the stability of transgene expression and long-term safety in 10 patients with severe hemophilia B: 6 patients who had been enrolled in an initial phase 1 dose-escalation trial, with 2 patients each receiving a low, intermediate, or high dose, and 4 additional patients who received the high dose (2×10(12) vector genomes per kilogram of body weight). The patients subsequently underwent extensive clinical and laboratory monitoring. RESULTS: A single intravenous infusion of vector in all 10 patients with severe hemophilia B resulted in a dose-dependent increase in circulating factor IX to a level that was 1 to 6% of the normal value over a median period of 3.2 years, with observation ongoing. In the high-dose group, a consistent increase in the factor IX level to a mean (±SD) of 5.1±1.7% was observed in all 6 patients, which resulted in a reduction of more than 90% in both bleeding episodes and the use of prophylactic factor IX concentrate. A transient increase in the mean alanine aminotransferase level to 86 IU per liter (range, 36 to 202) occurred between week 7 and week 10 in 4 of the 6 patients in the high-dose group but resolved over a median of 5 days (range, 2 to 35) after prednisolone treatment. CONCLUSIONS: In 10 patients with severe hemophilia B, the infusion of a single dose of AAV8 vector resulted in long-term therapeutic factor IX expression associated with clinical improvement. With a follow-up period of up to 3 years, no late toxic effects from the therapy were reported. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00979238.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further studies confirmed that the capsid-specific immune response is dose-dependent and administration of low vector doses of AAV are more likely to induce mild inflammation that is manageable by steroids [86–88].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [87]
In the citing paper
“The initial clinical studies of AAV-based gene transfer targeting liver correlated the AAV-specific cytotoxic T lymphocytes activation with transaminitis and loss of transgene expression”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“therefore studies of AAV immunogenicity focused mainly on the adaptive immune responses against AAV-transduced hepatocytes (38, 39).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [39]
In the citing paper
“Moreover, a recent meta-analysis of clinical trials using hepatic AAV gene transfer concluded that vectors rich in CpG motifs results in failure to achieve sustained expression, owing to activation of capsid specific CD8+ T cells (19–22).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“Antibody formation against capsid was also not impacted by CpG depletion in clinical trials (19, 57).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [19]
In the citing paper
“These studies however build evidence that short-course CCS alone is likely to be insufficient to inhibit formation of capsid-reactive T cells (13) and rAAV-mediated immune response with systemic high dosages.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
In the citing paper
“In the subsequent study using AAV8, administration of steroids was able to negate this response and maintain therapeutic FIX levels albeit a 50-70% decline from peak levels (13).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L. A., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Self-citationNathwani, A. C., Gray, J. T., Ng, C. Y., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball‐Cook, G., McIntosh, J., Boon‐Spijker, M., et al. (2005) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 419
Self-citationNathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationNathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2006) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,001
Pathogenic mechanisms and the prospect of gene therapy for choroideremia
Dimopoulos, I. S., Chan, S., MacLaren, R. E., & MacDonald, I. M. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1046434 · Cited by 37
State of the art: gene therapy of haemophilia
Spencer, H. T., Riley, B. E., & Doering, C. B. (2016) · Haemophilia · doi:10.1111/hae.13011 · Cited by 36
Gene therapy for glycogen storage diseases
Koeberl, D. D., Koch, R. L., Lim, J., Brooks, E. D., Arnson, B., Sun, B., & Kishnani, P. S. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12654 · Cited by 39
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 42
Self-citationGene therapy for hemophilia: past, present and future
George, L. A., & Fogarty, P. F. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.10.002 · Cited by 36
Haemophilia gene therapy: Progress and challenges
Lhériteau, E., Davidoff, A. M., & Nathwani, A. C. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.002 · Cited by 36
Self-citationJo, Y.-I., Suresh, B., Kim, S., & Ramakrishna, S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.09.003 · Cited by 36
Concise Review: The Potential Use of Intestinal Stem Cells to Treat Patients with Intestinal Failure
Hong, S. N., Dunn, J., Stelzner, M. G., & Martı́n, M. G. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0153 · Cited by 36
Emerging therapies for hemophilia: controversies and unanswered questions
Arruda, V. R., Doshi, B. S., & Samelson‐Jones, B. J. (2018) · F1000Research · doi:10.12688/f1000research.12491.1 · Cited by 37
CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs
Morishige, S., Mizuno, S., Ozawa, H., Nakamura, T., Mazahery, A. R., Nomura, K., Seki, R., Mouri, F., Osaki, K., Yamamura, K., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02765-0 · Cited by 37
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
Miesbach, W., & Klamroth, R. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s239810 · Cited by 36
Sutter, S. O., Lkharrazi, A., Schraner, E. M., Michaelsen, K., Meier, A. F., Marx, J., Vogt, B., Büning, H., & Fraefel, C. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010187 · Cited by 32
A snapshot of biologic drug development
Andrews, L., Ralston, S. L., Blomme, E. A. G., & Barnhart, K. F. (2015) · Human & Experimental Toxicology · doi:10.1177/0960327115603594 · Cited by 37
Efficient capsid antigen presentation from adeno-associated virus empty virions in vivo
Pei, X., Earley, L. F., He, Y., Chen, X., Hall, N. E., Samulski, R. J., & Li, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00844 · Cited by 35
“In considering this, the following factors may be important: (1) different environments between AAV transduced cells in vivo and in vitro including cell–cell interactions or cells with components around cells, (2) intracellular trafficking, and (3) the long-term interaction of AAV virions with cellular proteins.”
BackgroundButterfield, J. S. S., Yamada, K., Bertolini, T. B., Syed, F., Kumar, S. R. P., Li, X., Arisa, S., Piñeros, A. R., Tapia, A., Rogers, C. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.005 · Cited by 36
Słyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 40
Gene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 38
Extended half‐life clotting factor concentrates: results from published clinical trials
Young, G. A., & Mahlangu, J. N. (2016) · Haemophilia · doi:10.1111/hae.13028 · Cited by 35
Afzal, S., Wilkening, S., Kalle, C. V., Schmidt, M., & Fronza, R. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.001 · Cited by 35
Chen, M., Maeng, K., Nawab, A., Francois, R. A., Bray, J. K., Reinhard, M. K., Boye, S. L., Hauswirth, W. W., Kaye, F. J., Aslanidi, G., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.089 · Cited by 36
Mietzsch, M., Hering, H., Hammer, E.-M., Agbandje‐McKenna, M., Zolotukhin, S., & Heilbronn, R. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.164 · Cited by 35
Split Cas9, Not Hairs − Advancing the Therapeutic Index of CRISPR Technology
Schmelas, C., & Grimm, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700432 · Cited by 35
Lahey, H. G., Webber, C. J., Golebiowski, D., Izzo, C., Horn, E., Taghian, T., Rodríguez, P. M., Batista, A. R., Ellis, L. E., Hwang, M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.021 · Cited by 37
Progress in the contemporary management of hemophilia: The new issue of patient aging
Mannucci, P. M., & Iacobelli, M. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.05.012 · Cited by 35
Modifying immune responses to adeno-associated virus vectors by capsid engineering
Bentler, M., Hardet, R., Ertelt, M., Rudolf, D., Kaniowska, D., Schneider, A., Vondran, F. W. R., Schoeder, C. T., Delphin, M., Lucifora, J., et al. (2023) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.015 · Cited by 34
Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome
Ayuso, E. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.49 · Cited by 35
Establishment of two quantitative nested qPCR assays targeting the human EPO transgene
Neuberger, E. W. I., Perez, I. C., Guiner, C. L., Moser, D., Ehlert, T., Allais, M., Moullier, P., Simon, P. D., & Snyder, R. O. (2016) · Gene Therapy · doi:10.1038/gt.2016.2 · Cited by 34
Vectored antibody gene delivery for the prevention or treatment of HIV infection
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000145 · Cited by 35
Combining Gene and Stem Cell Therapy for Peripheral Nerve Tissue Engineering
Busuttil, F., Rahim, A. A., & Phillips, J. B. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0188 · Cited by 34
Pipe, S. W. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26865 · Cited by 35
Li, B., Ma, W., Ling, C., Vliet, K. V., Huang, L.-Y., Agbandje‐McKenna, M., Srivastava, A., & Aslanidi, G. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.115 · Cited by 35
Spronck, E. A., Liu, Y. P., Lubelski, J., Ehlert, E., Gielen, S., Montenegro-Miranda, P. S., de Haan, M., Nijmeijer, B. A., Ferreira, V., Petry, H., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.005 · Cited by 34
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 34
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
Emerging therapies for haemophilia ‐ Global perspective
Mahlangu, J. N., Cerquiera, M., & Srivastava, A. (2018) · Haemophilia · doi:10.1111/hae.13510 · Cited by 33
Nossair, F., & Thornburg, C. D. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718784830 · Cited by 33
Chan, J. K. Y., Gil-Fariña, I., Johana, N. B., Rosales, C., Tan, Y. W., Ceiler, J., McIntosh, J., Ogden, B. E., Waddington, S. N., Schmidt, M., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801391r · Cited by 34
Self-citationDevelopment of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B
Brown, H. C., Doering, C. B., Herzog, R. W., Ling, C., Markusic, D. M., Spencer, H. T., Srivastava, A., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.099 · Cited by 33
Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B
Bittel, D. C., Sreetama, S. C., Chandra, G., Ziegler, R. J., Nagaraju, K., der Meulen, J. H. V., & Jaiswal, J. K. (2022) · Journal of Clinical Investigation · doi:10.1172/jci141295 · Cited by 33
Zhang, L., Rossi, A., Lange, L., Meumann, N., Koitzsch, U., Christie, K. A., Nesbit, M. A., Moore, C. B. T., Hacker, U. T., Morgan, M. A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.027 · Cited by 33
Bočkor, L., Bortolussi, G., Iaconcig, A., Chiaruttini, G., Tiribelli, C., Giacca, M., Benvenuti, F., Zentilin, L., & Muro, A. F. (2017) · Gene Therapy · doi:10.1038/gt.2017.75 · Cited by 32
Synthetic Biology—Toward Therapeutic Solutions
Haellman, V., & Fussenegger, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.08.020 · Cited by 34
New approaches to gene and cell therapy for hemophilia
Ohmori, T., Mizukami, H., OZAWA, K., Sakata, Y., & Nishimura, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12926 · Cited by 33
Tersteeg, C., Verhenne, S., Roose, E., Schelpe, A., Deckmyn, H., Meyer, S. F. D., & Vanhoorelbeke, K. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1122515 · Cited by 32
Fischer, P. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00772 · Cited by 32
Marcó, S., Haurigot, V., & Bosch, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.217 · Cited by 35
Efficient in vivo editing of OTC-deficient patient-derived primary human hepatocytes
Ginn, S. L., Amaya, A. K., Liao, S. H. Y., Zhu, E., Cunningham, S. C., Lee, M., Hallwirth, C. V., Logan, G. J., Tay, S. S., Cesare, A. J., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.100065 · Cited by 32
Chen, J., An, B., Yu, B., Peng, X., Yuan, H., Yang, Q., Chen, X., Yu, T., Wang, L., Zhang, X., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.224063 · Cited by 32
AAV6 Vexosomes Mediate Robust Suicide Gene Delivery in a Murine Model of Hepatocellular Carcinoma
Khan, N., Maurya, S., Bammidi, S., & Jayandharan, G. R. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.006 · Cited by 32
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33
Khan, A., Aljarbou, A. N., Aldebasi, Y. H., Allemeilam, K. S., Alsahly, M. A., Khan, S., Alruwetei, A. M., & Khan, M. A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s256022 · Cited by 32
Yin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1744-6 · Cited by 33
Organoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
Ramamurthy, R. M., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011143 · Cited by 35
Gene therapy in an era of emerging treatment options for hemophilia B
Monahan, P. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12957 · Cited by 31
Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. K. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 32
Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract
Kurosaki, F., Uchibori, R., Mato, N., Sehara, Y., Saga, Y., Urabe, M., Mizukami, H., Sugiyama, Y., & Kume, A. (2017) · Gene Therapy · doi:10.1038/gt.2017.19 · Cited by 31
Hemophilia in a Changing Treatment Landscape
Pelland‐Marcotte, M., & Carcao, M. D. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.007 · Cited by 32
Toll-Like Receptors and Relevant Emerging Therapeutics with Reference to Delivery Methods
Javaid, N., Yasmeen, F., & Choi, S. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090441 · Cited by 31
Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease
Holthaus, S.-M. K., Herranz-Martín, S., Massaro, G., Aristorena, M., Hoke, J., Hughes, M. P., Maswood, R. N., Semenyuk, O., Basche, M., Shah, A. Z., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz210 · Cited by 31
Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders
Shomali, N., Gharibi, T., Vahedi, G., Mohammed, R. N., Mohammadi, H., Salimifard, S., & Marofi, F. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29324 · Cited by 30
In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
Breuer, C. B., Hanlon, K. S., Natasan, J.-S., Volak, A., Meliani, A., Mingozzi, F., Kleinstiver, B. P., Moon, J. J., & Maguire, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61518-w · Cited by 30
Self-citationProphylaxis for hemophilia A without inhibitors: treatment options and considerations
Valentino, L. A., & Khair, K. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1775576 · Cited by 32
Peplow, P., & Martinez, B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.310673 · Cited by 32
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective
Tomeo, F., Mariz, S., Brunetta, A. L., Stoyanova-Beninska, V. V., Penttilä, K., & Magrelli, A. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14838 · Cited by 30
An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
Sun, J., Shao, W., Chen, X., Merricks, E. P., Wimsey, L., Abajas, Y. L., Niemeyer, G. P., Lothrop, C. D., Monahan, P. E., Samulski, R. J., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.011 · Cited by 30
TLR9-independent CD8+ T cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling
Kumar, S. R. P., Biswas, M., Cao, D., Arisa, S., Muñoz-Melero, M., Lam, A. K., Piñeros, A. R., Kapur, R., Kaisho, T., Kaufman, R. J., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.029 · Cited by 31
Wu, Y., Chen, J., & Jong, Y. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01123-z · Cited by 32
Weinstein, D. A., Derks, T. G., Rodriguez‐Buritica, D. F., Ahmad, A., Couce, M., Mitchell, J. J., Riba‐Wolman, R., Mount, M., Sallago, J. B., Ross, K. M., et al. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70014 · Cited by 30
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 31
Self-citationGene therapy for hemophilia: Progress to date and challenges moving forward
Gollomp, K. L., Doshi, B. S., & Arruda, V. R. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.012 · Cited by 32
Treatment Options in Hemophilia
Miesbach, W., Schwäble, J., Müller, M. M., & Seifried, E. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0791 · Cited by 31
Lim, J., Choi, S. J., Gao, F., Kishnani, P. S., & Sun, B. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.034 · Cited by 30
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
Cantore, A., & Naldini, L. (2020) · Haemophilia · doi:10.1111/hae.14056 · Cited by 30
The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges
Trinchero, A., Sholzberg, M., & Matino, D. (2020) · Hämostaseologie · doi:10.1055/a-1175-6530 · Cited by 30
Human gene therapy: A scientometric analysis
Zhou, W., & Wang, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111510 · Cited by 31
Chen, N., Sun, K., Chemuturi, N. V., Cho, H., & Xia, C. Q. (2022) · The AAPS Journal · doi:10.1208/s12248-021-00678-7 · Cited by 30
Gene therapy for urea cycle defects: An update from historical perspectives to future prospects
Duff, C. E., Alexander, I. E., & Baruteau, J. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12609 · Cited by 30
Guen, V. L., Judor, J., Boeffard, F., Gauttier, V., Ferry, N., Soulillou, J., Brouard, S., & Conchon, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.11.019 · Cited by 34
Recombinant adeno-associated virus carrying thymosin β 4 suppresses experimental colitis in mice
Zheng, X., Lv, Y., Li, S., Li, Q., Zhang, Q.-N., Zhang, X., & Hao, Z. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i2.242 · Cited by 30
In Vivo Hematopoietic Stem Cell Transduction
Richter, M., Stone, D., Miao, C. H., Humbert, O., Kiem, H., Papayannopoulou, T., & Lieber, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.001 · Cited by 29
Risser, F., Urosev, I., López-Morales, J., Sun, Y., & Nash, M. A. (2022) · Biophysical Reviews · doi:10.1007/s12551-022-00950-w · Cited by 30
Two-Plasmid Packaging System for Recombinant Adeno-Associated Virus
Tang, Q., Keeler, A. M., Zhang, S., Su, Q., Lyu, Z., Cheng, Y., Gao, G., & Flotte, T. R. (2020) · BioResearch open access · doi:10.1089/biores.2020.0031 · Cited by 29
Selvaraj, N., Wang, C.-K., Bowser, B., Broadt, T. L., Shaban, S., Burns, J., Saptharishi, N., Pechan, P. A., Golebiowski, D., Alimardanov, A., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.054 · Cited by 29
Belov, A. A., Schultz, K. L. W., Forshee, R. A., & Tegenge, M. A. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12597 · Cited by 29
Goodman, C. S., Berntorp, E. E., & Wong, O. (2022) · Haemophilia · doi:10.1111/hae.14425 · Cited by 29
The promising novel therapies for familial hypercholesterolemia
Chen, R., Lin, S., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24552 · Cited by 30
Gene Therapy and Hemophilia: Where Do We Go from Here?
Bolous, N. S., Bhatt, N., Bhakta, N. H., Neufeld, E. J., Davidoff, A. M., & Reiss, U. M. (2022) · Journal of Blood Medicine · doi:10.2147/jbm.s371438 · Cited by 29
Self-citationGene therapy for hemophilia—opportunities and risks
Miesbach, W., Klamroth, R., Oldenburg, J., & Tiede, A. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0353 · Cited by 28
Clinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy
Sun, K., & Liao, M. Z. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2141 · Cited by 30
Hemophilia gene therapy: first, do no harm
Valentino, L. A., Kaczmarek, R., Pierce, G. F., Noone, D., O’Mahony, B., Page, D., Rotellini, D., & Skinner, M. W. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.06.016 · Cited by 29
Waddington, S. N., Peranteau, W. H., Rahim, A. A., Boyle, A. K., Kurian, M. A., Gissen, P., Chan, J. K. Y., & David, A. L. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12659 · Cited by 31
Callan, M. B., Haskins, M. E., Wang, P., Zhou, S., High, K. A., & Arruda, V. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151800 · Cited by 29
Self-citationChallenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III
Jauze, L., Monteillet, L., Mithieux, G., Rajas, F., & Ronzitti, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.102 · Cited by 34
Treating Bietti crystalline dystrophy in a high-fat diet-exacerbated murine model using gene therapy
Qu, B., Wu, S., Jiao, G., Zou, X., Li, Z., Guo, L., Sun, X., Huang, C., Sun, Z., Zhang, Y., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0159-3 · Cited by 29
Piechnik, M., Amendum, P. C., Sawamoto, K., Stapleton, M., Khan, S., Fnu, N., Álvarez, V., Pachon, A. M. H., Danos, O., Bruder, J. T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012693 · Cited by 28
Tanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27
Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps
Brimble, M. A., Cheng, P.-H., Winston, S. M., Reeves, I. L., Souquette, A., Spence, Y., Zhou, J., Wang, Y.-D., Morton, C. L., Valentine, M., et al. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.008 · Cited by 30
Self-citationImmune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
Cell-specific regulation of gene expression using splicing-dependent frameshifting
Ling, J. P., Bygrave, A. M., Santiago, C. P., Carmen‐Orozco, R. P., Trinh, V., Yu, M., Li, Y., Liu, Y., Bowden, K. D., Duncan, L. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33523-2 · Cited by 30
Metadata
- Authors
- Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., Pie, J., Rangarajan, S., Bevan, D., Recht, M., Shen, Y.-M., Halka, K. G., Basner-Tschakarjan, E., Mingozzi, F., High, K. A., Allay, J., Kay, M. A., Ng, C. Y. C., Zhou, J., Cancio, M., Morton, C. L., Gray, J. T., Srivastava, D., Nienhuis, A. W., & Davidoff, A. M.
- Affiliations
- NHS Blood and Transplant (GB)
- Royal Free London NHS Foundation Trust (GB)
- University College London (GB)
- St Thomas' Hospital (GB)
- Oregon Health & Science University (US)
- The University of Texas Southwestern Medical Center (US)
- Children's Hospital of Philadelphia (US)
- St. Jude Children's Research Hospital (US)
- Stanford Medicine (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1994-2004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4278802
- OpenAlex
- W1969271703
- Cited by
- 1,273
- References
- 17
- Citations by year
- 2026: 44 · 2025: 64 · 2024: 80 · 2023: 99 · 2022: 118 · 2021: 119 · 2020: 133 · 2019: 125 · 2018: 139 · 2017: 144 · 2016: 108 · 2015: 92 · 2014: 2
- FWCI
- 81.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Assisi Foundation of Memphis
- NHS Blood and Transplant
- American Lebanese Syrian Associated Charities
- National Institute for Health and Care Research (RP-PG-0310-1001, NF-SI-0513-10071)
- University College London
- University College London Hospitals NHS Foundation Trust
- Medical Research Council
- National Heart, Lung, and Blood Institute (HL094396, R01HL094396, R01HL073838, R01HL064274)
- National Cancer Institute (P30CA021765)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, AAV8 vector, self-complementary AAV, dose-response relationship, long-term safety, late toxicity, alanine aminotransferase elevation, bleeding events
- MeSH terms
- Dependovirus, Adult, Alanine Transaminase, Hemophilia B, Factor IX, Follow-Up Studies, Genetic Vectors, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Gene Expression, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
